Aarhus Universitet

Alessandra Zarantonello

Henrik Pedersen

Steffen Thiel

Nick Stub Laursen

Gregers Rom Andersen

Rasmus Kjeldsen Jensen

Dennis Vestergaard Pedersen

Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well as methods of treating disorders associated with complement activation.

Bispecific constructs for target and complement engagement

Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of Cq, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well as methods of treating disorders associated with complement activation.

Methods of treating complement-mediated disease

Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well 5 as methods of treating disorders associated with complement activation.

Growing community of inventors

Aarhus C, Denmark

Alessandra Zarantonello